Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity.
Lowe E, Anderl JL, Bade D, Delgado-Martin C, Dong C, Fan RA, Fang Y, Jiang J, Johnson HWB, Kempema A, McGilvray P, McMinn D, Millare B, Muchamuel T, Poweleit N, Qian Y, Rehan S, Scapin G, Sugahara A, Tranter D, Tuch B, Wang J, Wang L, Whang JA, Zuno-Mitchell P, Paavilainen VO, Park E, Taunton J, Kirk CJ, Anand NK.
Lowe E, et al. Among authors: tranter d.
J Pharmacol Exp Ther. 2025 Aug;392(8):103634. doi: 10.1016/j.jpet.2025.103634. Epub 2025 Jun 14.
J Pharmacol Exp Ther. 2025.
PMID: 40669140
Free article.